Literature DB >> 33302304

Chemical Modulators of Fibrinogen Production and Their Impact on Venous Thrombosis.

Rui Vilar1, Samuel W Lukowski1,2, Marco Garieri1, Corinne Di Sanza1, Marguerite Neerman-Arbez1,3, Richard J Fish1.   

Abstract

Thrombosis is a leading cause of morbidity and mortality. Fibrinogen, the soluble substrate for fibrin-based clotting, has a central role in haemostasis and thrombosis and its plasma concentration correlates with cardiovascular disease event risk and a prothrombotic state in experimental models. We aimed to identify chemical entities capable of changing fibrinogen production and test their impact on experimental thrombosis. A total of 1,280 bioactive compounds were screened for their ability to alter fibrinogen production by hepatocyte-derived cancer cells and a selected panel was tested in zebrafish larvae. Anthralin and all-trans retinoic acid (RA) were identified as fibrinogen-lowering and fibrinogen-increasing moieties, respectively. In zebrafish larvae, anthralin prolonged laser-induced venous- occlusion times and reduced thrombocyte accumulation at injury sites. RA had opposite effects. Treatment with RA, a nuclear receptor ligand, increased fibrinogen mRNA levels. Using an antisense morpholino oligonucleotide to deplete zebrafish fibrinogen, we correlated a shortening of laser-induced venous thrombosis times with RA treatment and fibrinogen protein levels. Anthralin had little effect on fibrinogen mRNA in zebrafish larvae, despite leading to lower detectable fibrinogen. Therefore, we made a proteomic scan of anthralin-treated cells and larvae. A reduced representation of proteins linked to the canonical secretory pathway was detected, suggesting that anthralin affects protein secretion. In summary, we found that chemical modulation of fibrinogen levels correlates with measured effects on experimental venous thrombosis and could be investigated as a therapeutic avenue for thrombosis prevention. Thieme. All rights reserved.

Entities:  

Year:  2020        PMID: 33302304      PMCID: PMC7982297          DOI: 10.1055/s-0040-1718414

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  50 in total

Review 1.  New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  New oral anticoagulant drugs in cardiovascular disease.

Authors:  Ingo Ahrens; Gregory Y H Lip; Karlheinz Peter
Journal:  Thromb Haemost       Date:  2010-06-10       Impact factor: 5.249

3.  [Experimental studies of the mechanism of action of reserpine].

Authors:  I S Chekman
Journal:  Biull Eksp Biol Med       Date:  1972-03

4.  Regulation of fibrinogen production by microRNAs.

Authors:  Alexandre Fort; Christelle Borel; Eugenia Migliavacca; Stylianos E Antonarakis; Richard J Fish; Marguerite Neerman-Arbez
Journal:  Blood       Date:  2010-06-22       Impact factor: 22.113

5.  Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.

Authors:  John Danesh; Sarah Lewington; Simon G Thompson; Gordon D O Lowe; Rory Collins; J B Kostis; A C Wilson; A R Folsom; K Wu; M Benderly; U Goldbourt; J Willeit; S Kiechl; J W G Yarnell; P M Sweetnam; P C Elwood; M Cushman; B M Psaty; R P Tracy; A Tybjaerg-Hansen; F Haverkate; M P M de Maat; F G R Fowkes; A J Lee; F B Smith; V Salomaa; K Harald; R Rasi; E Vahtera; P Jousilahti; J Pekkanen; R D'Agostino; W B Kannel; P W F Wilson; G Tofler; C L Arocha-Piñango; A Rodriguez-Larralde; E Nagy; M Mijares; R Espinosa; E Rodriquez-Roa; E Ryder; M P Diez-Ewald; G Campos; V Fernandez; E Torres; R Marchioli; F Valagussa; A Rosengren; L Wilhelmsen; G Lappas; H Eriksson; P Cremer; D Nagel; J D Curb; B Rodriguez; K Yano; J T Salonen; K Nyyssönen; T-P Tuomainen; B Hedblad; P Lind; H Loewel; W Koenig; T W Meade; J A Cooper; B De Stavola; C Knottenbelt; G J Miller; J A Cooper; K A Bauer; R D Rosenberg; S Sato; A Kitamura; Y Naito; T Palosuo; P Ducimetiere; P Amouyel; D Arveiler; A E Evans; J Ferrieres; I Juhan-Vague; A Bingham; H Schulte; G Assmann; B Cantin; B Lamarche; J-P Després; G R Dagenais; H Tunstall-Pedoe; M Woodward; Y Ben-Shlomo; G Davey Smith; V Palmieri; J L Yeh; A Rudnicka; P Ridker; F Rodeghiero; A Tosetto; J Shepherd; I Ford; M Robertson; E Brunner; M Shipley; E J M Feskens; D Kromhout; A Dickinson; B Ireland; K Juzwishin; S Kaptoge; S Lewington; A Memon; N Sarwar; M Walker; J Wheeler; I White; A Wood
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

6.  Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients.

Authors:  Najib Dally; Ron Hoffman; Nuhad Haddad; Galit Sarig; Jacob M Rowe; Benjamin Brenner
Journal:  Thromb Res       Date:  2005-01-12       Impact factor: 3.944

Review 7.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

8.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Retinoids stimulate fibrinogen production both in vitro (hepatocytes) and in vivo. Induction requires activation of the retinoid X receptor.

Authors:  E Nicodeme; M Nicaud; M Issandou
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-10       Impact factor: 8.311

10.  Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study.

Authors:  Jacqueline S Danik; Guillaume Paré; Daniel I Chasman; Robert Y L Zee; David J Kwiatkowski; Alex Parker; Joseph P Miletich; Paul M Ridker
Journal:  Circ Cardiovasc Genet       Date:  2009-02-12
View more
  2 in total

1.  Venous Thrombosis and Thrombocyte Activity in Zebrafish Models of Quantitative and Qualitative Fibrinogen Disorders.

Authors:  Richard J Fish; Cristina Freire; Corinne Di Sanza; Marguerite Neerman-Arbez
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

2.  Tetramethylpyrazine Protects Endothelial Injury and Antithrombosis via Antioxidant and Antiapoptosis in HUVECs and Zebrafish.

Authors:  Yafang Zhang; Cheng Ma; Linfeng He; Li Liao; Chaocheng Guo; Cheng Wang; Lihong Gong; Honglin Zhou; Ke Fu; Cheng Peng; Yunxia Li
Journal:  Oxid Med Cell Longev       Date:  2022-07-18       Impact factor: 7.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.